A THREE-PERIOD MULTICENTER STUDY, WITH A RANDOMIZED WITHDRAWAL, DOUBLE-BLINDED, PLACEBO-CONTROLLED DESIGN TO EVALUATE THE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF MAS825 IN PATIENTS WITH MONOGENIC IL-18 DRIVEN AUTOINFLAMMATORY DISEASES, INCLUDING NLRC4-GOF, XIAP DEFICIENCY, OR CDC42 MUTATIONS

Registry ID

CMAS825D12201

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2024-03-13

Last update

2022-08-25

Conditions

• AUTOIMMUNE DISEASE

Related clinical trials

• A PHASE 2/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ORAL BREPOCITINIB IN ADULTS WITH LICHEN PLANOPILARIS
• A PHASE 1 OPEN-LABEL, MULTIREGIONAL, MULTICENTER, BASKET STUDY EVALUATING THE SAFETY AND EFFICACY OF KITE-363, AN AUTOLOGOUS ANTI-CD19/CD20 CAR T-CELL THERAPY IN PARTICIPANTS WITH REFRACTORY AUTOIMMUNE DISEASES
• A PHASE 1 STUDY EVALUATING THE SAFETY AND PRELIMINARY EFFICACY OF ALLO- 329, A DUAL ANTI-CD19 / ANTI-CD70 ALLOGENEIC CAR T CELL PRODUCT IN AUTOIMMUNE DISEASE (RESOLUTION)
• A RANDOMIZED, TWO-PERIOD CROSSOVER STUDY TO DEMONSTRATE THE COMPARABILITY OF PHARMACOKINETICS OF SUBCUTANEOUS IANALUMAB BETWEEN 2ML AUTOINJECTOR/2ML PRE-FILLED SYRINGE WITH 1 ML PRE-FILLED SYRINGE IN ADULT PARTICIPANTS WITH AUTOIMMUNE DISEASE
• PHASE IB OPEN LABEL BASKET TRIAL OF RAY121 TO INHIBIT CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES (RAINBOW TRIAL)
• A PHASE IB STUDY OF NIVOLUMAB IN PATIENTS WITH AUTOIMMUNE DISORDERS AND ADVANCED MALIGNANCIES (AIM-NIVO)

View on source registry